Keywords: depression, glucagon-like peptide-1 (GLP-1), neuroinflammation, neurogenesis, synaptic plasticity Introduction Depression is emerging as one of the main causes of morbidity and mortality globally, and the number of individuals reported to be afflicted with the disorder continues to increase (Ledford, 2014
[DOI] [PMC free article] [PubMed] [Google Scholar] 88.Dutour A., Abdesselam I., Ancel P., Kober F., Mrad G., Darmon P., Ronsin O., Pradel V., Lesavre N., Martin J.C., et al
By making specific, intentional changes to how you eat and live, you can encourage your digestive system to produce more of this beneficial hormone
At least one manufacturer (PharmaTher) has announced it is targeting the full 0.252.4 mg dose range, suggesting Wegovy-equivalent generics are likely later in 2026 or in 2027
In this study, we studied patients with overweight or obesity initiating either semaglutide or tirzepatide between May 2022 and September 2023
Insurance coverage hinges on a diabetes diagnosis
